Cited by 149MicroRNA in disease regulationWnt/β-catenin signaling in development and cancerCancer-related molecular mechanisms research

The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer

Open access
Peng, Yin, Zhang, Xiaojing, Feng, Xianling, Fan, Xinmim, Jin, Zhe·2017·Oncotarget

Abstract

// Yin Peng 1,4,* , Xiaojing Zhang 1,3,* , Xianling Feng 1 , Xinmim Fan 1 and Zhe Jin 1,2,3 1 Department of Pathology, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 2 Shenzhen Key Laboratory of Micromolecule Innovatal Drugs, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 3 Shenzhen Key Laboratory of Translational Medicine in Tumors, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 4 Department of Pathology, Wuhan University School of Basic Medical Sciences, Hubei, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Zhe Jin, email: // Keywords : microRNA; Wnt/β-catenin signaling pathway; cancer Received : January 15, 2016 Accepted : October 21, 2016 Published : October 26, 2016 Abstract Mounting evidence has indicated microRNA (miR) dysregulation and the Wnt/β-catenin signaling pathway jointly drive carcinogenesis, cancer metastasis, and drug-resistance. The current review will focus on the role of the crosstalk between miRs and the Wnt/β-catenin signaling pathway in cancer development. MiRs were found to activate or inhibit the canonical Wnt pathway at various steps. On the other hand, Wnt activation increases expression of miR by directly binding to its promoter and activating transcription. Moreover, there are mutual feedback loops between some miRs and the Wnt/β-catenin signaling pathway. Clinical trials of miR-based therapeutic agents are investigated for solid and hematological tumors, however, challenges concerning low bioavailability and possible side effects must be overcome before the final clinical application. This review will describe current understanding of miR crosstalk with the Wnt/β-catenin signaling cascade. Better understanding of the regulatory network will provide insight into miR-based therapeutic development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12923

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

2 of the 162 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [157]Gan X Liu Z Tong B Zhou J Epigenetic downregulated ITGBL1 promotes non-small cell lung cancer cell invasion through Wnt/PCP signaling Tumour biology 2016 37 1663 1669 26307393

Cited by

Sorted by citations

Authors
Peng, Y., Zhang, X., Feng, X., Fan, X., & Jin, Z.
Affiliations
Shenzhen University (CN)
Corresponding author
  • Peng, Yin
  • Zhang, Xiaojing
Venue
Oncotarget
Published
2016-10-26
Volume
8
Issue
8
Pages
14089-14106
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2543491141
Cited by
149
References
162
Citations by year
2026: 9 · 2025: 16 · 2024: 9 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 18 · 2019: 15 · 2018: 13 · 2017: 17
FWCI
1.38
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (31601028)
  • Shenzhen Peacock Plan
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
microRNA, Wnt/β-catenin signaling, cancer, carcinogenesis, metastasis, drug resistance, transcriptional regulation, miRNA-based therapy, bioavailability
MeSH terms
Animals, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Receptor Cross-Talk, MicroRNAs, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review